Tripathy, D, Sara, T, Seidman, AD et al. (9 more authors) (2018) ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). In: Cancer Research. 2017 San Antonio Breast Cancer Symposium, 05-09 Dec 2017, San Antonio, Texas, U.S.A.. American Association for Cancer Research
Metadata
Item Type: | Proceedings Paper |
---|---|
Authors/Creators: |
|
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 11 Jul 2019 14:25 |
Last Modified: | 11 Jul 2019 15:01 |
Status: | Published |
Publisher: | American Association for Cancer Research |
Identification Number: | 10.1158/1538-7445.SABCS17-OT2-07-10 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:148292 |
Download not available
A full text copy of this item is not currently available from White Rose Research Online